全文获取类型
收费全文 | 16212篇 |
免费 | 1275篇 |
国内免费 | 464篇 |
专业分类
耳鼻咽喉 | 179篇 |
儿科学 | 76篇 |
妇产科学 | 232篇 |
基础医学 | 388篇 |
口腔科学 | 78篇 |
临床医学 | 2716篇 |
内科学 | 6754篇 |
皮肤病学 | 63篇 |
神经病学 | 147篇 |
特种医学 | 1017篇 |
外国民族医学 | 2篇 |
外科学 | 1956篇 |
综合类 | 1823篇 |
预防医学 | 490篇 |
眼科学 | 126篇 |
药学 | 647篇 |
3篇 | |
中国医学 | 183篇 |
肿瘤学 | 1071篇 |
出版年
2024年 | 41篇 |
2023年 | 368篇 |
2022年 | 442篇 |
2021年 | 706篇 |
2020年 | 702篇 |
2019年 | 689篇 |
2018年 | 603篇 |
2017年 | 595篇 |
2016年 | 632篇 |
2015年 | 610篇 |
2014年 | 1116篇 |
2013年 | 1151篇 |
2012年 | 862篇 |
2011年 | 957篇 |
2010年 | 794篇 |
2009年 | 814篇 |
2008年 | 826篇 |
2007年 | 834篇 |
2006年 | 822篇 |
2005年 | 696篇 |
2004年 | 594篇 |
2003年 | 496篇 |
2002年 | 426篇 |
2001年 | 335篇 |
2000年 | 269篇 |
1999年 | 249篇 |
1998年 | 236篇 |
1997年 | 201篇 |
1996年 | 155篇 |
1995年 | 127篇 |
1994年 | 131篇 |
1993年 | 96篇 |
1992年 | 71篇 |
1991年 | 66篇 |
1990年 | 34篇 |
1989年 | 47篇 |
1988年 | 29篇 |
1987年 | 22篇 |
1986年 | 18篇 |
1985年 | 23篇 |
1984年 | 13篇 |
1983年 | 8篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1973年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
目的 了解射频消融灶大小与功率及时间的关系、超声与大体病理测值的关系、消融灶与周围组织的关系。方法 新鲜牛肝 3只和牛肾 2只 ,消融灶分两组 :距肝表面 1cm和 4cm ;同时将肾脏置于肝表面 ,用不同的功率和时间实验。结果 10min时 ,2 0W ,40W ,6 0W ,80W的消融灶病理测值分别为 4.1cm ,3.8cm ,3.0cm ,3.3cm ,超声测值分别为 4.5cm ,4.0cm ,4.5cm ,4.0cm。 2 0min时 ,消融灶病理测值分别为 3.0cm ,4.1cm ,2 .8cm ,3.5cm ,超声测值分别为 4.3cm ,4.2cm ,3.4cm ,3.8cm。 30min时 ,消融灶病理测值分别为 3.5cm ,2 .9cm ,3.5cm ,3.4cm ,超声测值分别为 4.5cm ,4.0cm ,3.6cm ,4.1cm。超声和大体解剖测值相比 ,P <0 .0 1。消融灶和周围组织间有0 .3~ 0 .5cm的浅红色移行区。结论 射频消融灶的大小不随功率和时间的增加而增加 ,超声比大体病理测值大 ,两者差别有极显著性意义。消融病灶和周围组织间有移行区。浅表面的消融病灶对临近组织有损伤作用 相似文献
92.
目的采用Meta分析对比微波消融(MWA)与肝切除术(LR)治疗结直肠癌肝转移(CRCLM)的效果和安全性。方法检索PubMed、Embase、Cochrane Library、中国生物医学文献数据库、万方、中国知网、维普数据库关于MWA与LR治疗CRCLM的文献,检索时间自建库至2020年8月31日。依据纳入及排除标准筛选文献,以Review Manager 5.3和Stata 14软件进行Meta分析。结果最终纳入13篇文献、共1 534例CRCLM患者,MWA组685例,LR组849例。经异质性检验,1年总体生存率(OS)(I~2=0%,P=0.72)、3年OS(I~2=0%,P=0.86)、5年OS(I~2=0%,P=0.90)均无明显异质性,采用固定效应模型进行分析,结果显示MWA组与LR组间1年OS[HR=0.99,95%CI(0.95,1.02),P=0.44]、3年OS[HR=1.02,95%CI(0.93,1.11),P=0.74]差异均无统计学意义,LR组5年OS高于MWA组[HR=0.82,95%CI(0.69,0.97),P=0.02]。异质性检验示并发症无明显异质性(I~2=0%,P=0.78),以固定效应模型进行分析,结果显示MWA组并发症发生率低于LR组[RR=0.35,95%CI(0.23,0.52),P0.000 01)]。结论 MWA治疗CRCLM早、中期疗效(1、3年OS)与LR相当,远期疗效(5年OS)不及LR,但安全性更高。 相似文献
93.
目的 观察超声引导下经皮微波消融(MWA)治疗恶性胸、腹壁肿瘤的效果。方法 对11例恶性胸、腹壁肿瘤患者行超声引导下经皮MWA治疗,共治疗14个病灶,腹壁6个,胸壁8个;术后随访,观察治疗效果及不良反应。结果 11例超声引导下MWA治疗均成功,技术成功率100%。术后1个月8例治疗有效,3例肿瘤残存。2例术后出现局部疼痛,经对症治疗后缓解;1例局部脂肪液化,予局部消毒换药1个月后痊愈。未见气胸、肠道损伤、皮肤烧伤等严重并发症。4例术前合并病灶周围神经痛,术后疼痛得到有效控制。术后随访4~28个月,中位随访时间8个月;期间2例失访、2例死亡;至随访终点7例疗效较好,未见复发及转移。结论 超声引导下经皮MWA治疗恶性胸、腹壁肿瘤安全、有效。 相似文献
94.
影像学引导消融治疗已逐渐成为治疗不可切除实体肿瘤的重要方式,但消融治疗后存在肿瘤局部复发及全身转移风险。免疫治疗可通过增强机体自身免疫细胞功能间接清除肿瘤细胞,但多数实体肿瘤对免疫治疗的反应率较低。近年来,基于纳米材料的肿瘤消融技术发展迅速,为增强局部消融效果及提高系统免疫应答提供了新的可能。本文对基于纳米材料的消融联合免疫治疗肿瘤研究进展进行综述。 相似文献
95.
BackgroundBone tumors can cause severe pain and poor quality of life due to recurrence and non-achievement of complete remission after surgery, chemotherapy, or radiotherapy. Radiofrequency ablation (RFA) can be considered for minimally invasive treatment of bone tumors that are difficult to radically excise. In this study, RFA was performed for bone tumors that were difficult to radically excise and did not respond to surgery, chemotherapy, or radiotherapy due to their large sizes and/or locations. The purpose of this study was to retrospectively analyze the clinical characteristics and survival rates of bone tumors after RFA and provide one more treatment option for the future.MethodsThere were 43 patients with bone tumors who underwent percutaneous RFA at our hospital from April 2007 to October 2017. The median age of the patients was 59 years (range, 31–75 years), and the median follow-up duration was 67.2 months (range, 10.2–130.5 months). Of the 43 patients, 26 were male and 17 were female. Thirty-four cases were metastatic bone tumors, 5 were chordomas, 3 were osteosarcomas, and 1 was a giant cell tumor. Pain and functional ability of the patients were evaluated using a visual analog scale (VAS) and the Musculoskeletal Tumor Society (MSTS) functional scoring system, respectively. Scores were recorded preoperatively, 1 week postoperatively, and 4 weeks postoperatively. The 1-year, 2-year, and 5-year survival rates were evaluated using the Kaplan-Meier method.ResultsThe mean VAS score was 8.21 preoperatively. The mean VAS score at 1 week, 4 weeks, 12 weeks, and 24 weeks postoperatively were 3.91, 3.67, 3.31, and 3.12, respectively. The mean preoperative MSTS score was 64.0% (range, 32%–87%). The mean postoperative MSTS score was 71.0% (range, 40%–90%). The 1-year, 2-year, and 5-year survival rates were 95.3%, 69.8%, and 30.2%, respectively.ConclusionsAs per our study findings, RFA was effective in reducing pain and improving functional ability of patients with bone tumors that were difficult to radically excise. 相似文献
96.
T. Mayer R.L. Cazzato P. De Marini P. Auloge D. Dalili G. Koch J. Garnon A. Gangi 《Diagnostic and interventional imaging》2021,102(1):27-34
PurposeTo investigate the safety and clinical efficacy of bipolar radiofrequency ablation (b-RFA) with increased (> 70 °C) target temperature for the treatment of spine metastases with the intent of achieving pain relief or local tumor control.Materials and methodsThirty-one patients with a total of 37 metastases who were treated with b-RFA with increased temperature and vertebroplasty from January 2016 to May 2019 were retrospectively included. There were 20 women and 11 men with a mean age of 62.4 ± 10.5 (SD) years (range: 40–78 years). Patients and metastases characteristics, procedure details and clinical outcomes were analyzed.ResultsMetastases were predominantly located in lumbar (22/37; 59.5%) or thoracic spine (13/37; 35.1%). Mean target temperature was 88.4 ± 3.5 (SD) °C (range: 70–90 °C). Technical success was 100% (37/37 metastases). One (1/37; 2.7%) major complication unrelated to b-RFA was reported. One (1/37; 2.7%) metastasis was lost to follow-up. Favorable outcome was noted in patients receiving b-RFA for pain management (16/20 metastases; 80%; mean follow-up, 3.4 ± 2.9 [SD] months) or with oligometastatic/oligoprogressive disease (6/6 metastases; 100%; mean follow-up, 5.0 ± 4.6 [SD] months). In patients receiving b-RFA to prevent complications, favorable outcome was noted in 6/10 metastases (60%; mean follow-up, 3.8 ± 4.8 [SD] months).ConclusionsB-RFA with increased target temperature has an excellent safety profile and results in high rates of pain relief and local metastasis control in patients with oligometastatic/oligoprogressive disease. Suboptimal results are achieved in patients receiving b-RFA to prevent complications related to the growth of the index tumor. 相似文献
97.
IntroductionAbdominal surgery uses various energy devices for vessel sealing, tissue dissection, and detachment. Currently, Acrosurg Revo® (Nikkiso Co., Ltd., Tokyo, Japan), a novel energy device using microwaves, has been developed for use in laparoscopic surgery. This report describes the early clinical experience of using this device in two cases of laparoscopic surgery.Presentation of caseCase 1 was of a 64-year-old woman who underwent laparoscopic abdominal incisional hernia repair. Case 2 was of a 56-year-old man with a diagnosis of ascending and sigmoid colon cancer who underwent laparoscopic right hemicolectomy and sigmoid colectomy with D3 dissection. Each surgery was completed using Acrosurg Revo® and an endoscopic electrosurgical unit. The postoperative course was uneventful, and both patients were discharged from the hospital without any complications.DiscussionWith this new and novel device, vessel sealing, hemostasis, coagulation, tissue dissection, and detachment were all possible. Notably, there was no spark or mist that hindered the surgical field of view. Furthermore, because microwave coagulation did not result in tissue carbonization, there was a considerable decrease in device tip contamination.ConclusionThe Acrosurg Revo® may be a useful energy device for laparoscopic surgery. 相似文献
98.
99.
目的探讨经皮侧后路椎间孔镜下髓核摘除术治疗青少年腰椎间盘突出症的临床疗效。方法 2010年2月~2011年7月,我院收治的12例青少年腰椎间盘突出症患者接受了经皮侧后路椎间孔镜下髓核摘除术治疗并获得随访。其中男8例,女4例;年龄12~20岁,平均14.6岁。比较手术前后Oswestry功能障碍指数(Oswestry Disability Index,ODI)、下肢疼痛视觉模拟评分(visual analogue scale,VAS)及术后12个月时Macnab评分对临床疗效进行分析。结果 12例患者均获得随访,随访时间17~30个月,平均21.3个月。术后1周、3个月,6个月,12个月及末次随访时ODI指数、下肢疼痛VAS评分与术前相比均明显降低,差异有统计学意义(P0.05)。按照Macnab评分标准,术后12个月时,优7例,良4例,可1例,优良率为91.7%(11/12)。结论经皮侧后路椎间孔镜下髓核摘除术治疗青少年腰椎间盘突出症短期内能取得满意的临床疗效,其长期疗效及安全性有待进一步研究。 相似文献